bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide | 211513-15-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide
• 英文别名: dalcetrapib thiol dimer；(N,N'-(dithiodi-2,1-phenylene)bis[1-(2-ethylbutyl)-cyclohexanecarboxamide])；N,N'-(dithiodi-2,1-phenylene)bis[1-(2-ethylbutyl)-cyclohexanecarboxamide]；N,N'-(dithiodi-2,1-phenylene)bis[1-(2-ethylbutyl)cyclohexanecarboxamide]；1-(2-ethylbutyl)-N-[2-[[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl]disulfanyl]phenyl]cyclohexane-1-carboxamide
• CAS: 211513-15-4
• 化学式: C₃₈H₅₆N₂O₂S₂
• 分子量: 637.007
• InChiKey: CWOUDBOBZZCQFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.7
• 重原子数：
  44
• 可旋转键数：
  15
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide 以89.3的产率得到达塞曲匹
  参考文献：
  名称：

  NOVEL PROCESS

  摘要：

  本发明涉及一种制备S-[2-[1-(2-乙基丁基)环己基甲酰氨基]-苯基] 2-甲基硫代丙酸酯的方法，该化合物是一种有用的药物活性化合物。

  公开号：

  US20130338391A1
• 作为产物：
  描述：

  2-乙基溴代丁烷 在 吡啶 、 草酰氯 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.5h， 生成 bis-[2-[1-(2-ethylbutyl)cyclohexanecarbonylamino]phenyl]disulfide
  参考文献：
  名称：

  Bis(2-(Acylamino)phenyl) Disulfides, 2-(Acylamino)benzenethiols, and S-(2-(Acylamino)phenyl) Alkanethioates as Novel Inhibitors of Cholesteryl Ester Transfer Protein

  摘要：

  A series of bis(2-(acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, S-(2-(acylamino)phenyl) alkanethioates, and related compounds were synthesized, and their inhibitory effect on cholesteryl ester transfer protein activity in human plasma was evaluated. This study elucidated the structural requirements for inhibitory activity and determined that the optimum compound was S-(2-((1-(2-ethylbutyl)cyclohexane)carbonylamino)phenyl) 2-methylpropanethioate (27) (JTT-705). This compound achieved 50% inhibition of CETP activity in human plasma at a concentration of 9 mu M and 95% inhibition of CETP activity in male Japanese white rabbits at an oral dose of 30 mg/kg. It increased the plasma HDL cholesterol level by 27% and 54%, respectively, when given at oral doses of 30 or 100 mg/kg once a day for 3 days to male Japanese white rabbits.

  DOI：

  10.1021/jm000224s

文献信息

• GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
  申请人：GEMPHIRE THERAPEUTICS INC.

  公开号：US20180297929A1

  公开（公告）日：2018-10-18

  This present invention provides gemcabene pharmaceutically acceptable salts having a PSD90 of 35 μm to about 90 μm, methods for purifying crude gemcabene, pharmaceutically acceptable salts of purified gemcabene, pharmaceutical compositions of a gemcabene pharmaceutically acceptable salt and therapeutic and prophylactic methods useful for various conditions, including dyslipidemia.

  这项发明提供了具有35μm至约90μm的PSD90的gemcabene药用可接受盐，用于纯化粗制gemcabene的方法，纯化后的gemcabene的药用可接受盐，gemcabene药用可接受盐���药物组合物，以及用于治疗和预防各种疾病的治疗和预防方法，包括脂质代谢异常。
• NOVEL PROCESS
  申请人：Lohri Bruno

  公开号：US20090312569A1

  公开（公告）日：2009-12-17

  The present invention relates to a process for the preparation of 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid which is useful as an intermediate in the preparation of pharmaceutically active compounds.

  本发明涉及一种制备1-(2-乙基-丁基)-环己基甲酸的方法，该方法在制备药用活性化合物中作为中间体时非常有用。
• CETP inhibitors in combination with antihypertensive agents and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040039018A1

  公开（公告）日：2004-02-26

  This invention relates to pharmaceutical combinations of a cholesteryl ester transfer protein (CETP) inhibitor or a pharmaceutically acceptable salt thereof; and an antihypertensive agent or a pharmaceutically acceptable salt thereof, optionally in combination with an HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from atherosclerosis, peripheral vascular disease, dyslipidemia, hyperbetaliproteinemia, hypoalphalipoproteinemia, hypercholesterolemia, hypertriglyceridemia, familial-hypercholesterolemia, cardiovascular disorders, angina, ischemia, cardiac ischemia, stroke, myocardial infarction, reperfusion injury, angioplastic restenosis, hypertension, vascular complications of diabetes, obesity or endotoxemia in a mammal (including a human being either male or female).

  本发明涉及一种胆固醇酯转移蛋白（CETP）抑制剂或其药学上可接受的盐与降压药剂或其药学上可接受的盐的药物组合，可选地与HMG CoA还原酶抑制剂或其药学上可接受的盐的药物组合，包含这种组合的套件以及使用这种组合治疗患有动脉粥样硬化、外周血管疾病、血脂异常、高β脂蛋白血症、低α脂蛋白血症、高胆固醇血症、高三酰甘油血症、家族性高胆固醇血症、心血管疾病、心绞痛、缺血、心肌缺血、中风、心肌梗死、再灌注损伤、血管成形术再狭窄、高血压、糖尿病血管并发症、肥胖或内毒素血症的哺乳动物（包括男性或女性人类）的使用方法。
• Methods of treatment with CETP inhibitors and antihypertensive agents
  申请人：Pfizer Inc.

  公开号：US20040053842A1

  公开（公告）日：2004-03-18

  This invention relates to cholesterol ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors, and the use of such inhibitors to treat certain disease/conditions optionally in combination with certain therapeutic agents e.g., antihypertensive agents.

  本发明涉及胆固醇酯转移蛋白（CETP）抑制剂，含有这种抑制剂的药物组合物，以及使用这种抑制剂治疗某些疾病/症状，可选择性地与某些治疗药物如降压药物结合使用。
• New Process
  申请人：Mair Hans-Juergen

  公开号：US20120157504A1

  公开（公告）日：2012-06-21

  The present invention relates to a process for the preparation of S-[2-[1-(2-ethylbutyl)cyclohexylcarbonylamino]-phenyl]2-methylthiopropionate which is useful as a pharmaceutically active compound.

  本发明涉及一种制备S-[2-[1-(2-乙基丁基)环己基甲酰氨基]-苯基]2-甲基硫代丙酸酯的方法，该化合物可用作药物活性化合物。